Search

Search Constraints

You searched for: Author/Creator Kong, Jessica

Search Results

2. Baseline biomarker (tau PET) characteristics from TANGO: A phase 2 trial of gosuranemab (BIIB092) in early Alzheimer's disease. (1st February 2022)

3. Baseline biomarker (tau PET) characteristics from TANGO: A phase 2 trial of gosuranemab (BIIB092) in early Alzheimer's disease. (December 2021)

4. Baseline characteristics from TANGO: Phase 2 study to evaluate gosuranemab (BIIB092) in patients with early Alzheimer's disease: Human: Improving clinical trial methodology. (7th December 2020)

5. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing–remitting multiple sclerosis: findings from the CONFIRM study. (February 2014)

6. Exploratory evaluation of 18F‐MK‐6240 tau PET positivity in TANGO phase 2 clinical trial of gosuranemab (BIIB092) in Mild Cognitive Impairment and mild Alzheimer's disease. (20th December 2022)

7. P3‐033: RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED STUDY TO ASSESS TREATMENT OF BIIB092 IN SUBJECTS WITH EARLY ALZHEIMER'S DISEASE: TANGO PHASE 2 STUDY DESIGN. (1st July 2006)